Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2
Tóm tắt
The COVID-19 pandemic worldwide has resulted in over 176 million cases and roughly 3.8 million deaths so far. We could analyze mutation dynamics across the genome from countries such as the USA, Italy, the UK, France, Brazil, and India considering the rapid mutations of the SARS-CoV-2 genome. The analysis would help us to understand the genome diversity, the implications of the mutations in protein stability, and viral transmission. Among the 11 genes, surface glycoprotein (S) was singled out because of its crucial function associated with the entry of virion into the human cell upon binding with the hACE2 receptor. 749 S protein sequences from India were retrieved from the NCBI database for our study. The S protein is an important antigenic component responsible for inducing host immune responses, neutralizing antibodies, and providing protective immunity against viral infection. During an epitope prediction from a mutation-prone S-protein region, it is necessary to ascertain how new mutations significantly change the S protein, such that our vaccine is effective against all the mutated strains as well. The S1 region of the S protein had been our prime focus for identifying immune epitopes against SARS-COV-2. Antigenic B- cell epitopes were YYPDKVF from NTD and LFRKSNLKP from RBD. Cytotoxic T-cell epitopes WTAGAAAYY (within NTD) and CVADYSVLY (within RBD) exhibited binding with a maximum number of MHC I alleles. The T-cell epitopes which showed a maximum affinity for MHC II alleles were FLPFFSNVT within NTD and YFPLQSYGF within RBD. Furthermore, the best epitopes were characterized in terms of their physicochemical properties to establish their potentiality.
Tài liệu tham khảo
Abdullahi IN, Emeribe AU, Ajayi OA, et al. Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions. J Taibah Univ Med Sci. 2020;15:258–64. https://doi.org/10.1016/j.jtumed.2020.06.005.
Ashik AI, Hasan M, Tasnim AT, et al. An immunoinformatics study on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates. Heliyon. 2020;6: e04865. https://doi.org/10.1016/j.heliyon.2020.e04865.
Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015;31:2745–7. https://doi.org/10.1093/bioinformatics/btv195.
Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol. 2006;47:45–148. https://doi.org/10.1002/9780470122921.ch2.
Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21:73–82. https://doi.org/10.1038/s41577-020-00480-0.
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8:1–7. https://doi.org/10.1186/1471-2105-8-4.
Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985;55:836–9. https://doi.org/10.1128/jvi.55.3.836-839.1985.
Guruprasad L. Human SARS CoV-2 spike protein mutations. Proteins Struct Funct Bioinform. 2021;89:569–76. https://doi.org/10.1002/prot.26042.
Gutierrez L, Beckford J, Alachkar H. Deciphering the TCR repertoire to solve the COVID-19 mystery. Trends Pharmacol Sci. 2020;41:518–30. https://doi.org/10.1016/j.tips.2020.06.001.
Huang Y, Yang C, Feng XX, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141–9. https://doi.org/10.1038/s41401-020-0485-4.
Jensen KK, Andreatta M, Marcatili P, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154:394–406. https://doi.org/10.1111/imm.12889.
Karplus PA, Schulz GE. Prediction of chain flexibility in proteins: a tool for the selection of peptide antigens. Naturwissenschaften. 1985;72:212–3. https://doi.org/10.1007/BF01195768.
Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990;276:172–4. https://doi.org/10.1016/0014-5793(90)80535-Q.
Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19. J Transl Med. 2020;18:1–9. https://doi.org/10.1186/s12967-020-02520-8.
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20. https://doi.org/10.1038/s41586-020-2180-5.
Larsen JEP, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2:2. https://doi.org/10.1186/1745-7580-2-2.
Larsen MV, Lundegaard C, Lamberth K, et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform. 2007;8:1–12. https://doi.org/10.1186/1471-2105-8-424.
Mallick A, Chakrabarti J, Mandal S. Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. Microbes Infect. 2020;22(2020):598–607. https://doi.org/10.1016/j.micinf.2020.10.004.
Nagy Á, Pongor S, Győrffy B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. Int J Antimicrob Agents. 2021;57:4. https://doi.org/10.1016/j.ijantimicag.2020.106272.
Pandey RK, Bhatt TK, Prajapati VK. Novel immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein. Sci Rep. 2018;8:1–11. https://doi.org/10.1038/s41598-018-19456-1.
Peck KM, Lauring AS. Complexities of viral mutation rates. J Virol. 2018;92:1–8. https://doi.org/10.1128/jvi.01031-17.
Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020. https://doi.org/10.1016/j.meegid.2020.104260.
Ponomarenko J, Bui HH, Li W, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform. 2008;9:1–8. https://doi.org/10.1186/1471-2105-9-514.
Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV: a comparative overview. Infez Med. 2020;28:174–84.
Ranasinghe S, Lamothe PA, Soghoian DZ, et al. Antiviral CD8+ T cells restricted by human leukocyte antigen class II exist during natural HIV infection and exhibit clonal expansion. Immunity. 2016;45:917–30. https://doi.org/10.1016/j.immuni.2016.09.015.
Rasmussen SA. A novel coronavirus outbreak of global health concern. Ann Oncol. 2020. https://doi.org/10.1016/S0140-6736(20)30185-9.
Rehman Z, Fahim A, Bhatti MF. Scouting the receptor-binding domain of SARS coronavirus 2: a comprehensive immunoinformatics inquisition. Future Virol. 2021;16:117–32. https://doi.org/10.2217/fvl-2020-0269.
Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res. 2017. https://doi.org/10.1155/2017/2680160.
Singh PK, Kulsum U, Rufai SB, et al. Mutations in SARS-CoV-2 leading to antigenic variations in spike protein: a challenge in vaccine development. J Lab Phys. 2020;12:154–60. https://doi.org/10.1055/s-0040-1715790.
Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058.
Xu J, McPartlon M, Li J. Improved protein structure prediction by deep learning irrespective of co-evolution information. bioRxiv. 2020. https://doi.org/10.1101/2020.10.12.336859.
Yang Z, Bogdan P, Nazarian S. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. Sci Rep. 2021;11:1–21. https://doi.org/10.1038/s41598-021-81749-9.
Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020;39:198–216. https://doi.org/10.1007/s10930-020-09901-4.
Zhang L, Jackson CB, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11:1–9. https://doi.org/10.1038/s41467-020-19808-4.